Mesoblast Revenue Per Share from 2010 to 2025

MESO Stock  USD 18.96  1.16  5.77%   
Mesoblast Revenue Per Share yearly trend continues to be very stable with very little volatility. Revenue Per Share is likely to drop to 0.01. Revenue Per Share is the amount of revenue generated by Mesoblast per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
0.006879
Current Value
0.006535
Quarterly Volatility
0.02603055
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.6 M, Interest Expense of 24.9 M or Selling General Administrative of 20.5 M, as well as many indicators such as Price To Sales Ratio of 122, Dividend Yield of 0.0 or PTB Ratio of 1.5. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Latest Mesoblast's Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of Mesoblast over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. Mesoblast's Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mesoblast's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.0610 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

Mesoblast Revenue Per Share Regression Statistics

Arithmetic Mean0.03
Geometric Mean0.02
Coefficient Of Variation86.31
Mean Deviation0.02
Median0.03
Standard Deviation0.03
Sample Variance0.0007
Range0.0782
R-Value(0.53)
Mean Square Error0.0005
R-Squared0.29
Significance0.03
Slope(0)
Total Sum of Squares0.01

Mesoblast Revenue Per Share History

2025 0.006535
2024 0.006879
2023 0.005982
2022 0.0101
2021 0.0157
2020 0.0123
2019 0.0598

About Mesoblast Financial Statements

Mesoblast investors utilize fundamental indicators, such as Revenue Per Share, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Revenue Per Share 0.01  0.01 

Pair Trading with Mesoblast

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.

Moving against Mesoblast Stock

  0.78DNLI Denali TherapeuticsPairCorr
  0.76JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.66UPC Universe PharmaceuticalsPairCorr
  0.6FOLD Amicus TherapeuticsPairCorr
  0.58IONS Ionis PharmaceuticalsPairCorr
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.